Earnings Per Share, Diluted of Revance Therapeutics, Inc. from 31 Dec 2012 to 30 Sep 2024

Taxonomy & unit
us-gaap: USD/shares
Description
The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
Summary
Revance Therapeutics, Inc. quarterly and annual Earnings Per Share, Diluted in USD/shares history and change rate from 31 Dec 2012 to 30 Sep 2024.
  • Revance Therapeutics, Inc. Earnings Per Share, Diluted for the quarter ending 30 Sep 2024 was -0.37, a 77% increase year-over-year.
  • Revance Therapeutics, Inc. Earnings Per Share, Diluted for the twelve months ending 30 Sep 2024 was -2, a 61% increase year-over-year.
  • Revance Therapeutics, Inc. annual Earnings Per Share, Diluted for 2023 was -3.83, a 22% increase from 2022.
  • Revance Therapeutics, Inc. annual Earnings Per Share, Diluted for 2022 was -4.9, a 18% decline from 2021.
  • Revance Therapeutics, Inc. annual Earnings Per Share, Diluted for 2021 was -4.17, a 14% increase from 2020.
Source SEC data
View on sec.gov
Earnings Per Share, Diluted, Trailing 12 Months (USD/shares)
Earnings Per Share, Diluted, Quarterly (USD/shares)
Earnings Per Share, Diluted, YoY Quarterly Change (%)
Earnings Per Share, Diluted, Annual (USD/shares)
Earnings Per Share, Diluted, YoY Annual Change (%)

Revance Therapeutics, Inc. Quarterly Earnings Per Share, Diluted (USD/shares)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2024 -2 -0.37 +1.26 +77% 01 Jul 2024 30 Sep 2024 10-Q 07 Nov 2024 2024 Q3
Q2 2024 -3 -0.36 +0.44 +55% 01 Apr 2024 30 Jun 2024 10-Q 08 Aug 2024 2024 Q2
Q1 2024 -4 -0.58 +0.16 +22% 01 Jan 2024 31 Mar 2024 10-Q 09 May 2024 2024 Q1
Q4 2023 -4 -0.66 +1.25 +65% 01 Oct 2023 31 Dec 2023 10-K 28 Feb 2024 2023 FY
Q3 2023 -5 -1.63 -0.46 -39% 01 Jul 2023 30 Sep 2023 10-Q 07 Nov 2024 2024 Q3
Q2 2023 -5 -0.8 +0.08 +9.1% 01 Apr 2023 30 Jun 2023 10-Q 08 Aug 2024 2024 Q2
Q1 2023 -5 -0.74 +0.2 +21% 01 Jan 2023 31 Mar 2023 10-Q 09 May 2024 2024 Q1
Q4 2022 -5 -1.91 -0.99 -108% 01 Oct 2022 31 Dec 2022 10-K 28 Feb 2024 2023 FY
Q3 2022 -4 -1.17 -0.07 -6.4% 01 Jul 2022 30 Sep 2022 10-Q 08 Nov 2023 2023 Q3
Q2 2022 -4 -0.88 +0.19 +18% 01 Apr 2022 30 Jun 2022 10-Q 08 Aug 2023 2023 Q2
Q1 2022 -4 -0.94 +0.14 +13% 01 Jan 2022 31 Mar 2022 10-Q 09 May 2023 2023 Q1
Q4 2021 -4 -0.92 +0.33 +26% 01 Oct 2021 31 Dec 2021 10-K 28 Feb 2024 2023 FY
Q3 2021 -5 -1.1 +0.24 +18% 01 Jul 2021 30 Sep 2021 10-Q 08 Nov 2022 2022 Q3
Q2 2021 -5 -1.07 +0.05 +4.5% 01 Apr 2021 30 Jun 2021 10-Q 09 Aug 2022 2022 Q2
Q1 2021 -5 -1.08 +0.07 +6.1% 01 Jan 2021 31 Mar 2021 10-Q 10 May 2022 2022 Q1
Q4 2020 -5 -1.25 01 Oct 2020 31 Dec 2020 10-K 28 Feb 2023 2022 FY
Q3 2020 -1.34 01 Jul 2020 30 Sep 2020 10-Q 09 Nov 2021 2021 Q3
Q2 2020 -1.12 01 Apr 2020 30 Jun 2020 10-Q 05 Aug 2021 2021 Q2
Q1 2020 -1.15 01 Jan 2020 31 Mar 2020 10-Q 10 May 2021 2021 Q1
Q3 2016 -3 -0.64 +0.17 +21% 01 Jul 2016 30 Sep 2016 10-Q 04 Nov 2016 2016 Q3
Q2 2016 -3 -0.88 -0.17 -24% 01 Apr 2016 30 Jun 2016 10-Q 05 Aug 2016 2016 Q2
Q1 2016 -3 -0.71 -0.06 -9.2% 01 Jan 2016 31 Mar 2016 10-Q 10 May 2016 2016 Q1
Q4 2015 -3 -0.83 -0.23 -38% 01 Oct 2015 31 Dec 2015 10-K 04 Mar 2016 2015 FY
Q3 2015 -3 -0.81 -0.21 -35% 01 Jul 2015 30 Sep 2015 10-Q 04 Nov 2016 2016 Q3
Q2 2015 -3 -0.71 -0.02 -2.9% 01 Apr 2015 30 Jun 2015 10-Q 05 Aug 2016 2016 Q2
Q1 2015 -3 -0.65 +1.28 +66% 01 Jan 2015 31 Mar 2015 10-Q 10 May 2016 2016 Q1
Q4 2014 -4 -0.6 +46.51 +99% 01 Oct 2014 31 Dec 2014 10-K 04 Mar 2016 2015 FY
Q3 2014 -50 -0.6 +55.3 +99% 01 Jul 2014 30 Sep 2014 10-K 04 Mar 2016 2015 FY
Q2 2014 -106 -0.69 +74.56 +99% 01 Apr 2014 30 Jun 2014 10-K 04 Mar 2016 2015 FY
Q1 2014 -180 -1.93 -22.93 -109% 01 Jan 2014 31 Mar 2014 10-K 04 Mar 2016 2015 FY
Q4 2013 -157 -47.11 01 Oct 2013 31 Dec 2013 10-K 04 Mar 2015 2014 FY
Q3 2013 -55.9 01 Jul 2013 30 Sep 2013 10-K 04 Mar 2015 2014 FY
Q2 2013 -75.25 01 Apr 2013 30 Jun 2013 10-K 04 Mar 2015 2014 FY
Q1 2013 21 01 Jan 2013 31 Mar 2013 10-K 04 Mar 2015 2014 FY

Revance Therapeutics, Inc. Annual Earnings Per Share, Diluted (USD/shares)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2023 -3.83 +1.07 +22% 01 Jan 2023 31 Dec 2023 10-K 28 Feb 2024 2023 FY
2022 -4.9 -0.73 -18% 01 Jan 2022 31 Dec 2022 10-K 28 Feb 2024 2023 FY
2021 -4.17 +0.69 +14% 01 Jan 2021 31 Dec 2021 10-K 28 Feb 2024 2023 FY
2020 -4.86 -1.19 -32% 01 Jan 2020 31 Dec 2020 10-K 28 Feb 2023 2022 FY
2019 -3.67 01 Jan 2019 31 Dec 2019 10-K 28 Feb 2022 2021 FY
2015 -3.02 +0.22 +6.8% 01 Jan 2015 31 Dec 2015 10-K 04 Mar 2016 2015 FY
2014 -3.24 -4.29 -409% 01 Jan 2014 31 Dec 2014 10-K 04 Mar 2016 2015 FY
2013 1.05 +2.42 01 Jan 2013 31 Dec 2013 10-K 04 Mar 2016 2015 FY
2012 -1.37 01 Jan 2012 31 Dec 2012 10-Q 07 Aug 2015 2015 Q2
* An asterisk sign (*) next to the value indicates that the value is likely invalid.